IL-18 inhibition for promotion of early hematopoietic progenitor expansion
AssigneesThe General Hospital Corporation, President and Fellows of Harvard College
InventorsDavid T. Scadden, Lev Silberstein, Peter Kharchenko
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of IL-18 to a recipient subject and also administering hematopoietic stem/progenitor cells to the subject. Another method involves administering an inhibitor of IL-18 to a donor prior to harvest of hematopoietic stem/progenitor cells. Pharmaceutical compositions relating to the methods are also described.
Claims20
A method for enhancing hematopoietic reconstitution of a subject in need thereof comprising:
- a) administering to the subject hematopoietic stem/progenitor cells (HSPC) obtained from the blood, placenta or umbilical cord of a donor;
- and
- b) administering to the subject a therapeutically effective amount of an inhibitor of interleukin 18 (IL-18) to thereby inhibit IL-18 interaction with IL-18R molecules present on the HSPC administered in step a).
A method for enhanced hematopoietic reconstitution in a subject in need thereof comprising administering to the subject hematopoietic stem/progenitor cells (HSPC) obtained from a donor subject, wherein the donor subject was treated with an inhibitor of interleukin 18 (IL-18) to thereby expand early hematopoietic progenitor cells prior to harvest of the HSPCs from the donor.
A method for enhancing hematopoietic reconstitution of a subject in need thereof comprising:
- a) administering to the subject autologous hematopoietic stem/progenitor cells (HSPC);
- and
- b) administering to the subject a therapeutically effective amount of an inhibitor of interleukin 18 (IL-18) to thereby inhibit IL-18 interaction with IL-18R molecules present on the HSPC administered in step a).
Dependencies are inferred from the claim text.